Eagle Pharmaceuticals’ Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM® Rapid Infusion Liquid Bendamustine Formulation
Eagle Pharmaceuticals, Inc. (EGRX)
Last eagle pharmaceuticals, inc. earnings: 3/2 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.eagleus.com
Company Research
Source: Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that its marketing partner SymBio Pharmaceuticals Limited (“SymBio”) has completed patient enrollment in a clinical trial for TREAKISYM rapid infusion (“RI”), a liquid bendamustine injection with a 10-minute administration time, in Japan. The study’s primary objective is to confirm the safety of the RI product. SymBio expects to obtain regulatory approval in the second half of 2022.SymBio intends to submit a New Drug Application (“NDA”) for the RI product for all indications for which TREAKISYM is currently approved (low-grade non-Hodgkin’s lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia). As previously disclosed, SymBio filed an NDA for its TREAKISYM ready-to-dilute (“RTD”) product in October 2019.In September 2017, Eagle licensed to SymBio intellectual property necessary to develop, market and sell RTD and RI formulations of TREAKISYM in J
Show less
Read more
Impact Snapshot
Event Time:
EGRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EGRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EGRX alerts
High impacting Eagle Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
EGRX
News
- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
EGRX
Sec Filings
- 12/10/24 - Form EFFECT
- 12/2/24 - Form 8-K
- 11/27/24 - Form RW
- EGRX's page on the SEC website